Advancements in Intranasal Drug Delivery: Hovione and IDC Launch Commercial Platform

Hovione and IDC have announced that their Intranasal Drug Delivery platform has advanced to commercial readiness, with the lead single-use nasal dry powder device now available for partnerships. This integrated solution combines API development, particle engineering, formulation, capsule filling, and device supply, enabling partners to use existing infrastructure while cutting costs, risks, and development timelines.

Targeted Deposition for Systemic and Brain Delivery

The platform’s single-use device employs a patented mechanism for precise deposition across the nasal cavity, including the upper olfactory region, supporting rapid systemic absorption and potential nose-to-brain pathways. Early patent grants have been secured, and a multi-dose version is in development to expand use across therapies. This approach merges nasal particle engineering with manufacturing and device technologies, improving predictability for complex Intranasal Drug Delivery programs.

Efficient Manufacturing for Nasal Powders

Device design and initial manufacturing capabilities are complete, allowing partners to leverage existing capsule-filling lines without major new investment. Complementary in-vitro and analytical tools help address deposition, absorption, and retention challenges. These advances will be presented at the Respiratory Drug Delivery 2026 workshop, highlighting how combined expertise from Hovione and IDC reduces technology transfers and supports scalable production.

Lowering Barriers to Nasal Therapy Access

By simplifying development and manufacturing, the platform can accelerate commercialization of intranasal therapies and improve health-economic outcomes through greater efficiency and reliability. Hovione and IDC’s Intranasal Drug Delivery Platform offers a streamlined path that may enhance patient access and support stronger reimbursement positioning.